A Decade of Advances in Treatment for Advanced Non-Small Cell Lung Cancer

Clinics in Chest Medicine

Volumn 32, Issue 4, 2011, Pages 839-851

  Gettinger, Scott ^a   Lynch, Thomas ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE CANCER CENTER   (United States)

Author keywords

Anaplastic lymphoma kinase; Epidermal growth factor receptor; ERCC1; Lung cancer; Personalized; Targeted

Indexed keywords

5 (2,4 DIHYDROXY 5 ISOPROPYLPHENYL) 4 (4 MORPHOLINOMETHYLPHENYL) 3 ISOXAZOLECARBOXYLIC ACID ETHYLAMIDE; ADENOSINE TRIPHOSPHATE; AFATINIB; AUY 922; B RAF KINASE; BEVACIZUMAB; BRCA1 PROTEIN; CETUXIMAB; CISPLATIN; CRIZOTINIB; DACOMITINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEFITINIB; GEMCITABINE; MM 121; MONOCLONAL ANTIBODY; PACLITAXEL; PEMETREXED; RIBONUCLEOTIDE REDUCTASE; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG; VASCULOTROPIN; XL 184;

ACUTE LEUKEMIA; ADVANCED CANCER; ALOPECIA; BRAIN CANCER; CANCER MORTALITY; CHRONIC MYELOID LEUKEMIA; CIGARETTE SMOKING; COMPUTER ASSISTED TOMOGRAPHY; ESOPHAGUS CANCER; HIGH RISK PATIENT; HUMAN; LIVER CANCER; LUNG NON SMALL CELL CANCER; MULTIPLE MYELOMA; NEUTROPENIA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; THORAX RADIOGRAPHY; TUMOR GROWTH; UTERINE CERVIX CANCER;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 80455176700     PISSN: 02725231     EISSN: 15578216     Source Type: Journal    
DOI: 10.1016/j.ccm.2011.08.017     Document Type: Review

References (84)

1. Jemal A., Siegel R., Xu J., et al. Cancer Statistics, 2010. CA Cancer J Clin 2010, 60(5):277-300.
2. Available at: Accessed April 1, 2011. http://www.cancer.gov/newscenter/pressreleases/2011/NLSTresultsRel.
3. Wakelee H.A., Chang E.T., Gomez S.L., et al. Lung cancer incidence in never smokers. J Clin Oncol 2007, 25(5):472-478.
4. Barnes P.M., Heyman K.M., Freeman G., et al. Early release of selected estimates based on data from the 2009 National Health Interview Survey 2010, National Center for Health Statistics, Hyattsville (MD), Available at:, Accessed August 27, 2011. http://www.cdc.gov/nchs/nhis.htm.
5. Beasley M.B., Brambilla E., Travis W.D. The 2004 World Health Organization classification of lung tumors. Semin Roentgenol 2005, 40(2):90-97.
6. Altekruse S.F., Kosary C.L., Krapcho M. SEER Cancer Statistics Review, 1975-2007 2010, National Cancer Institute, Available at:, Accessed April 1, 2011. http://seer.cancer.gov/csr/1975_2007/.
7. Sandler A., Gray R., Perry M.C., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355(24):2542-2550.
8. Johnson D.H., Fehrenbacher L., Novotny W.F., et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004, 22(11):2184-2191.
9. Sandler A.B., Schiller J.H., Gray R., et al. Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab. J Clin Oncol 2009, 27(9):1405-1412.
10. Hanna N., Shepherd F.A., Fossella F.V., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004, 22(9):1589-1597.
11. Scagliotti G.V., Parikh P., von Pawel J., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26(21):3543-3551.
12. Petersen P., Park K., Fossella F.V., et al. Is pemetrexed more effective in adenocarcinoma and large cell lung cancer than in squamous cell carcinoma? A retrospective analysis of a phase III trial of pemetrexed versus docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC). 12th World Conference on Lung Cancer. J Thorac Oncol 2007, P2:328.
13. Ciuleanu T., Brodowicz T., Zielinski C., et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009, 374(9699):1432-1440.
14. Simon G.R., Sharma S., Cantor A., et al. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 2005, 127(3):978-983.
15. Olaussen K.A., Dunant A., Fouret P., et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006, 355(10):983-991.
16. Chen S., Zhang J., Wang R., et al. The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis. Lung Cancer 2010, 70(1):63-70.
17. Cobo M., Isla D., Massuti B., et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 2007, 25(19):2747-2754.
18. Zheng Z., Chen T., Li X., et al. DNA Synthesis and Repair Genes RRM1 and ERCC1 in Lung Cancer. N Engl J Med 2007, 356(8):800-808.
19. Bepler G., Kusmartseva I., Sharma S., et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol 2006, 24(29):4731-4737.
20. Davidson J.D., Ma L., Flagella M., et al. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res 2004, 64(11):3761-3766.
21. Rosell R., Scagliotti G., Danenberg K.D., et al. Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene 2003, 22(23):3548-3553.
22. Souglakos J., Boukovinas I., Taron M., et al. Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine. Br J Cancer 2008, 98(10):1710-1715.
23. Bepler G., Sommers K.E., Cantor A., et al. Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer. J Thorac Oncol 2008, 3(10):1112-1118.
24. Simon G., Sharma A., Li X., et al. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol 2007, 25(19):2741-2746.
25. Strauss G.M., Herndon J.E., Maddaus M.A., et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 2008, 26(31):5043-5051.
26. Mountain C.F. Revisions in the international system for staging lung cancer. Chest 1997, 111(6):1710-1717.
27. Powell S.N., Kachnic L.A. Roles of BRCA1 and BRCA2 in homologous recombination, DNA replication fidelity and the cellular response to ionizing radiation. Oncogene 2003, 22(37):5784-5791.
28. Le Page F., Randrianarison V., Marot D., et al. BRCA1 and BRCA2 are necessary for the transcription-coupled repair of the oxidative 8-oxoguanine lesion in human cells. Cancer Res 2000, 60(19):5548-5552.
29. Antoniou A., Pharoah P.D., Narod S., et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003, 72(5):1117-1130.
30. Antoniou A.C., Cunningham A.P., Peto J., et al. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer 2008, 98(8):1457-1466.
31. Taron M., Rosell R., Felip E., et al. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet 2004, 13(20):2443-2449.
32. Quinn J.E., Kennedy R.D., Mullan P.B., et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 2003, 63(19):6221-6228.
33. Quinn J.E., James C.R., Stewart G.E., et al. BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin Cancer Res 2007, 13(24):7413-7420.
34. Stordal B., Davey R. A systematic review of genes involved in the inverse resistance relationship between cisplatin and paclitaxel chemotherapy: role of BRCA1. Curr Cancer Drug Targets 2009, 9(3):354-365.
35. Rosell R., Perez-Roca L., Sanchez J.J., et al. Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression. PLoS One 2009, 4(5):e5133.
36. Wang B., Matsuoka S., Ballif B.A., et al. Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response. Science 2007, 316(5828):1194-1198.
37. Sobhian B., Shao G., Lilli D.R., et al. RAP80 targets BRCA1 to specific ubiquitin structures at DNA damage sites. Science 2007, 316(5828):1198-1202.
38. Kim H., Chen J., Yu X. Ubiquitin-binding protein RAP80 mediates BRCA1-dependent DNA damage response. Science 2007, 316(5828):1202-1205.
39. Rosell R., Skrzypski M., Jassem E., et al. BRCA1: a novel prognostic factor in resected non-small-cell lung cancer. PLoS One 2007, 2(11):e1129.
40. Sigmond J., Backus H.H., Wouters D., et al. Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression. Biochem Pharmacol 2003, 66(3):431-438.
41. Giovannetti E., Mey V., Nannizzi S., et al. Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol 2005, 68(1):110-118.
42. Hanauske A.R., Eismann U., Oberschmidt O., et al. In vitro chemosensitivity of freshly explanted tumor cells to pemetrexed is correlated with target gene expression. Invest New Drugs 2007, 25(5):417-423.
43. Ceppi P., Volante M., Saviozzi S., et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 2006, 107(7):1589-1596.
44. Olayioye M.A., Neve R.M., Lane H.A., et al. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000, 19(13):3159-3167.
45. Isobe T., Herbst R.S., Onn A. Current management of advanced non-small cell lung cancer: targeted therapy. Semin Oncol 2005, 32(3):315-328.
46. Kris M.G., Natale R.B., Herbst R.S., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003, 290(16):2149-2158.
47. Fukuoka M., Yano S., Giaccone G., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 2003, 21(12):2237-2246. [corrected].
48. Thatcher N., Chang A., Parikh P., et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005, 366(9496):1527-1537.
49. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353(2):123-132.
50. Cappuzzo F., Ciuleanu T., Stelmakh L., et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010, 11(6):521-529.
51. Pirker R., Pereira J.R., Szczesna A., et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009, 373(9674):1525-1531.
52. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350(21):2129-2139.
53. Paez J.G., Janne P.A., Lee J.C., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304(5676):1497-1500.
54. Pao W., Miller V., Zakowski M., et al. EGF receptor gene mutations are common in lung cancers from " never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004, 101(36):13306-13311.
55. Mok T.S., Wu Y.L., Thongprasert S., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361(10):947-957.
56. Maemondo M., Inoue A., Kobayashi K., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362(25):2380-2388.
57. Mitsudomi T., Morita S., Yatabe Y., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11(2):121-128.
58. Zhou C, Wu YL, Chen G, et al. Efficacy results from the randomised phase III OPTIMAL (CTONG 0802) study comparing first-line erlotinib versus carboplatin plus gemcitabine, in chinese advanced non-small-cell lung cancer patients with EGFR activating mutations ESMO 2010 [abstract LBA13]. Program and abstracts of the 35th European Society of Medical Oncology Congress 2010. Milan (Italy): European Society of Medical Oncology 2010 Abstract LBA 13.
59. Pao W., Miller V.A. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 2005, 23(11):2556-2568.
60. Pham D., Kris M.G., Riely G.J., et al. Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. J Clin Oncol 2006, 24(11):1700-1704.
61. Shigematsu H., Lin L., Takahashi T., et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005, 97(5):339-346.
62. Rosell R., Moran T., Queralt C., et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009, 361(10):958-967.
63. Riely G.J., Kris M.G., Zhao B., et al. Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res 2007, 13(17):5150-5155.
64. Kurata T., Tamura K., Kaneda H., et al. Effect of re-treatment with gefitinib ('Iressa', ZD1839) after acquisition of resistance. Ann Oncol 2004, 15(1):173-174.
65. Yano S., Nakataki E., Ohtsuka S., et al. Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: a report of three cases. Oncol Res 2005, 15(2):107-111.
66. Kobayashi S., Boggon T.J., Dayaram T., et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005, 352(8):786-792.
67. Pao W., Miller V.A., Politi K.A., et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005, 2(3):e73.
68. Arcila M.E., Oxnard G.R., Nafa K., et al. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res 2011, 17(5):1169-1180.
69. Sequist L.V., Waltman B.A., Dias-Santagata D., et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011, 3(75):75ra26.
70. Yun C.H., Mengwasser K.E., Toms A.V., et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A 2008, 105(6):2070-2075.
71. Sos M.L., Rode H.B., Heynck S., et al. Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation. Cancer Res 2010, 70(3):868-874.
72. Bean J., Brennan C., Shih J.Y., et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 2007, 104(52):20932-20937.
73. Engelman J.A., Zejnullahu K., Mitsudomi T., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316(5827):1039-1043.
74. Morris S.W., Kirstein M.N., Valentine M.B., et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994, 263(5151):1281-1284.
75. Shiota M., Fujimoto J., Semba T., et al. Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3. Oncogene 1994, 9(6):1567-1574.
76. Soda M., Choi Y.L., Enomoto M., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448(7153):561-566.
77. Kwak E.L., Bang Y.J., Camidge D.R., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363(18):1693-1703.
78. Camidge DR, Bang YJ, Iafrate AJ, et al. Clinical activity of crizotinib (PF-02341066), in ALK-positive patients with advanced non-small cell lung cancer [abstract 366PD]. Program and abstracts of the 35th European Society of Medical Oncology Congress 2010. Milan (Italy): European Society of Medical Oncology; 2010.
79. Shaw A.T., Yeap B.Y., Mino-Kenudson M., et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009, 27(26):4247-4253.
80. Choi Y.L., Soda M., Yamashita Y., et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010, 363(18):1734-1739.
81. Weinstein I.B. Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 2002, 297(5578):63-64.
82. Pao W., Iafrate A.J., Su Z. Genetically informed lung cancer medicine. J Pathol 2011, 223(2):230-240.
83. Pao W., Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol 2011, 12(2):175-180.
84. Molecular Profiling of Lung Cancer. Available at: Accessed April 1, 2011. http://www.vicc.org/mycancergenome/nsclc/.